Patents by Inventor Marcin Dyba

Marcin Dyba has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • K-Ras modulators
    Patent number: 11358940
    Abstract: Provided herein are the K-Ras inhibitors of the formulae: Also provided are compositions comprising thereof for treating cancer.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: June 14, 2022
    Assignees: The Regents of the University of California, Leidos Biomedical Research, Inc.
    Inventors: Frank McCormick, Adam Renslo, David Turner, Anna E. Maciag, Marcin Dyba, Elizabeth D. Vo, Joseph Saavedra, Vandana Kumari
  • K-RAS MODULATORS
    Publication number: 20200247762
    Abstract: Provided herein, inter alia, are methods and compounds for modulating K-Ras treating cancer.
    Type: Application
    Filed: April 20, 2018
    Publication date: August 6, 2020
    Inventors: Frank MCCORMICK, Adam RENSLO, David TURNER, Anna E. MACIAG, Marcin DYBA, Elizabeth D. VO, Joseph SAAVEDRA, Vandana KUMARI
  • Azonafide derived tumor and cancer targeting compounds
    Patent number: 8008316
    Abstract: An azonafide-based compound of Formula I, a composition comprising the compound, and a method of using the compound to deliver a cytotoxic azonafide derivative to a cell, as well as related compounds and methods for the use thereof to pre-pare an azonafide-based compound of Formula I.
    Type: Grant
    Filed: September 12, 2007
    Date of Patent: August 30, 2011
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Nadya I. Tarasova, Marcin Dyba, Christopher J. Michejda, Maria Michejda, legal representative
  • AZONAFIDE DERIVED TUMOR AND CANCER TARGETING COMPOUNDS
    Publication number: 20100120817
    Abstract: An azonafide-based compound of Formula I, a composition comprising the compound, and a method of using the compound to deliver a cytotoxic azonafide derivative to a cell, as well as related compounds and methods for the use thereof to pre-pare an azonafide-based compound of Formula I.
    Type: Application
    Filed: September 12, 2007
    Publication date: May 13, 2010
    Applicant: Office of Technology Transfer, NIH
    Inventors: Nadya I. Tarasova, Marcin Dyba, Christopher J. Michejda, Maria Michejda
  • Conjugates of ligand linker and cytotoxic agent and related composition and methods of use
    Publication number: 20050171014
    Abstract: A conjugate comprising a ligand, a linker, and a cytotoxic agent, in which the linker is FALA, VLALA, ALAL, ALALA, ChaLALA, ChaChaLAL, NalChaLAL or NalLALA; a composition thereof; a method of delivering a cytotoxic agent in a cell-specific manner; and a method of treating cancer in a mammal.
    Type: Application
    Filed: February 27, 2003
    Publication date: August 4, 2005
    Applicant: Government of the United States of America, represented by the Secretary, Department of Health
    Inventors: Nadya Tarasova, Christopher Michejda, Marcin Dyba, Carolyn Cohran